Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Norwegian biotech company Affitech has reported positive pre-clinical results for R3, a fully human monoclonal antibody, in a pancreatic cancer model.
Subscribe to our email newsletter
The R3 antibody, generated by Affitech and tested by Peregrine Pharmaceuticals, has been designed by the two companies for selective blocking of VEGF (vascular endothelial growth factor) binding to VEGF receptor 2, as opposed to other anti-angiogenic agents which block activity of both VEGF receptors.
The antibody showed a significant reduction of the growth, vascularization and macrophage infiltration of pancreatic tumors in mice, the company said. Peregrine added that the positive results of R3 antibody support the company’s intent to progress its anti-VEGF program towards clinical trials.
Martin Welschof, CEO of Affitech, said: “We are delighted with this in vivo result. Affitech and Peregrine have several collaborative antibody projects. The quality of the antibody and excellent collaborative research by the scientists of our two organizations are contributing to advancing Peregrine’s anti-VEGF portfolio.”